Abstract Details

Title The Economic Impact of Multiple Sclerosis: A Preliminary Look at the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) (On behalf of the NARCRMS Health Economics Outcomes Research [HEOR] Advisory Group)

Topic Multiple Sclerosis

Presentation(s) P4 - Poster Session 4 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-065

Objective Define the economic impact of having MS, namely the impact on employment and utilization of healthcare resources.

Background NARCRMS enrolled its first patient in December 2016. Along with clinical and imaging data, NARCRMS collects information about the health care economics of patients with MS and its effects on daily life. Examination of the economic impact of MS provides useful information that affects the allocation of resources towards patient care.

Design/Methods

NARCRMS established the Health Economics Outcomes Research (HEOR) Advisory Group in 2017 to assist our industry partners in implementing HEOR in decision-making processes. NARCRMS developed a Health-Related Productivity Questionnaire and Health Resource Utilization Questionnaire. They were incorporated into the Case Report Forms (CRFs) and are completed at enrollment, annual and exacerbation visits for each patient.

Results As of October 18, 2018, 245 people with MS were enrolled and 225 completed the HEOR CRFs. Among those patients who completed the HEOR CRFs, 170 are employed, 25 reported that MS kept them from work, 52 reported that MS impacted their work and 62 reported that MS kept them from completing household chores. Fatigue was the leading symptom reported to impact both work and household chores. In the three months prior to reporting, 8 patients were hospitalized, 14 patients visited the emergency room, 47 patients visited a general practitioner and 185 patients visited a neurologist.

Conclusions A preliminary review of the first 225 patients to complete the HEOR CRFs found that 75.5% are employed however 23.5% were underemployed or unemployed due to MS. MS seems to prevent people with MS from realizing their full potential at work/home. Overwhelmingly, fatigue was identified as the cause for this problem. The economic impact of identifying an effective treatment for this symptom of MS cannot be overstated.

Authors/Disclosures
Terrie Livingston, PharmD (EMD Serono) PRESENTER	Ms. Livingston has received personal compensation for serving as an employee of Octave Bioscience. Ms. Livingston has received personal compensation for serving as an employee of EMD Serono. Ms. Livingston has stock in Biogen. Ms. Livingston has stock in Octave Bioscience.
Yang Mao-Draayer, MD (University of Michigan, Department of Neurology)	Dr. Mao-Draayer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen Idec. Dr. Mao-Draayer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme-Sanofi. Dr. Mao-Draayer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Mao-Draayer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genzyme-Sanofi. Dr. Mao-Draayer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Mao-Draayer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizone. Dr. Mao-Draayer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen Idec. The institution of Dr. Mao-Draayer has received research support from NIH .
Kottil W. Rammohan, MD (University of Miami)	Dr. Rammohan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Rammohan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Rammohan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Rammohan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Rammohan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme. Dr. Rammohan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. The institution of Dr. Rammohan has received research support from Genentech. The institution of Dr. Rammohan has received research support from Genzyme. The institution of Dr. Rammohan has received research support from EMD Serono. The institution of Dr. Rammohan has received research support from Alexion.
David K. Li, MD (University of British Columbia)	Dr. Li has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Li has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen. Dr. Li has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Academy of Health Care Learning. Dr. Li has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi-Genzyme. Dr. Li has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Consortium of MS Centers.
June Halper, RN, ANP (CMSC)	Ms. Halper has nothing to disclose.
Sara McCurdy Murphy	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��